Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel E Jacobs

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Psychopharmacology|November 4, 2021
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressantsTomasz Cholewinski, Diana Pereira, Matthijs Moerland, et al.
The Lancet. Psychiatry|August 29, 2016
Question-based Drug Development for psilocybinFrancis M Dijkstra, Gabriel E Jacobs, Adam F Cohen
Annals of Intensive Care|September 4, 2016
Unsuspected serotonin toxicity in the ICUCatharina E van Ewijk, Gabriel E Jacobs, Armand R J Girbes
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2018
[Valproic acid toxicity due to misinterpretation of plasma levels: increase in unbound fraction caused by hypoalbuminaemia and renal dysfunction]Roos Ruiter-Visser, Annemieke Dols, Yvo M Smulders, et al.
Digital Biomarkers|February 26, 2020
A Pilot Study Evaluating the Physiological Parameters of Performance-Induced Stress in Undergraduate Music StudentsEsther M van Fenema, Pim Gal, Maxime V van de Griend, et al.
Psychotherapy and Psychosomatics|July 25, 2018
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic ReviewRenske C Bosman, Ruth C Waumans, Gabriel E Jacobs, et al.
Clinical Pharmacokinetics|January 15, 2025
Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc AnalysisMarije E Otto, Katelijne V van der Heijden, Jan W Schoones, et al.
Clinical Pharmacokinetics|February 21, 2025
Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc AnalysisMarije E Otto, Katelijne V van der Heijden, Jan W Schoones, et al.
Translational Psychiatry|July 23, 2023
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorderKasper Recourt, Peter de Boer, Peter van der Ark, et al.
Cells|October 28, 2025
Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human StudiesPauline Nettesheim, Krishna C Vadodaria, Kimberly E Vanover, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Psychopharmacology|November 4, 2021
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressantsTomasz Cholewinski, Diana Pereira, Matthijs Moerland, et al.
The Lancet. Psychiatry|August 29, 2016
Question-based Drug Development for psilocybinFrancis M Dijkstra, Gabriel E Jacobs, Adam F Cohen
Annals of Intensive Care|September 4, 2016
Unsuspected serotonin toxicity in the ICUCatharina E van Ewijk, Gabriel E Jacobs, Armand R J Girbes
Nederlands Tijdschrift Voor Geneeskunde|September 14, 2018
[Valproic acid toxicity due to misinterpretation of plasma levels: increase in unbound fraction caused by hypoalbuminaemia and renal dysfunction]Roos Ruiter-Visser, Annemieke Dols, Yvo M Smulders, et al.
Digital Biomarkers|February 26, 2020
A Pilot Study Evaluating the Physiological Parameters of Performance-Induced Stress in Undergraduate Music StudentsEsther M van Fenema, Pim Gal, Maxime V van de Griend, et al.
Psychotherapy and Psychosomatics|July 25, 2018
Failure to Respond after Reinstatement of Antidepressant Medication: A Systematic ReviewRenske C Bosman, Ruth C Waumans, Gabriel E Jacobs, et al.
Clinical Pharmacokinetics|January 15, 2025
Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc AnalysisMarije E Otto, Katelijne V van der Heijden, Jan W Schoones, et al.
Clinical Pharmacokinetics|February 21, 2025
Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc AnalysisMarije E Otto, Katelijne V van der Heijden, Jan W Schoones, et al.
Translational Psychiatry|July 23, 2023
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorderKasper Recourt, Peter de Boer, Peter van der Ark, et al.
Cells|October 28, 2025
Biomarker-Based Pharmacological Characterization of ENX-102, a Novel α2/3/5 Subtype-Selective GABAA Receptor Positive Allo-Steric Modulator: Translational Insights from Rodent and Human StudiesPauline Nettesheim, Krishna C Vadodaria, Kimberly E Vanover, et al.
Pageof 2